News

In the News

  • 09.05.2018  |  Summit Therapeutics nominates CARB-X-funded SMT-571 as lead clinical candidate for treatment of gonorrhoea

    NASDAQ | Summit Therapeutics has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. SMT-571 represents a new antibiotic class. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option.

    Full Story

  • 07.03.2018  |  MicuRx files IPO on Hong Kong exchange

    ENDPOINTS NEWS l Shanghai- and San Francisco-based MicuRx has filed an IPO on the Hong Kong stock exchange to raise funds to advance its antibiotic contezolid acefosamil MRX-4 program, and also invest further in its CARB-X-backed preclinical polymicin antibiotic project.

    Full Story

  • 06.19.2018  |  Life sciences sector focus for UK-US event

    GOV.UK | UK Secretary of State Dr. Liam Fox discusses how the UK is committed to the continued growth of the life sciences sector by highlighting measures such as the £20 million in funding the government has pledged to the joint UK-US CARB-X project to address the global rise of antimicrobial resistance.

    Full Story

  • 06.08.2018  |  An Unlikely Biotech Investor: The Government

    FORBES | The Biomedical Advanced Research and Development Authority (BARDA) has launched a new funding initiative called DRIVe (Division of Research, Innovation and Ventures). DRIVe’s mission is to accelerate research, development and availability of transformative countermeasures to protect Americans in the event of public health emergencies such as chemical, biological, radiological, or nuclear disasters or attacks. The DRIVe initiative builds on BARDA’s involvement in CARB-X. A commentary by Steve Brozak.

    Full Story

  • 05.31.2018  |  Dept. of Existential threats. Who’s worried about Superbugs?

    INSIDE PHILANTHROPY | The involvement of the UK government and the Bill & Melinda Gates Foundation in CARB-X, with funding of more than $50 million over the next three years, underscores the growing concern about the global threat posed by superbugs. This is a challenge with implications for all the world’s countries, rich and poor alike.  

    Full Story

  • 05.22.2018  |  By 2050 one person will die every three seconds if we don’t tackle antibiotic resistance

    THE TELEGRAPH | We need a united, “one world”, “one health”, multisector response and it requires everyone and every country to stand up and play their part in the response. What is at stake here is nothing less than the basic integrity of modern medicine. A commentary by Professor Dame Sally Davies.

    Full Story

  • 05.22.2018  |  Government pledges more than £30m to fight superbugs

    THE TELEGRAPH | The UK government has given the fight against deadly superbugs a boost with a pledge of £31m for the development of new drugs and diagnostics, including a £20m award to CARB-X, the world’s leading public-private partnership dedicated to supporting antibacterial research to combat drug-resistance.

    Full Story

  • 04.11.2018  |  Innovative ways to pay for new antibiotics will help fight superbugs

    STAT | Although we’ve made great strides in the development of antibiotics since the discovery of penicillin in the early 20th century, we aren’t keeping up with the rise of superbugs — common bacteria that have acquired genes that make them resistant to most or all of our antibiotics. A commentary by Kevin Outterson.

    Full Story

  • 03.30.2018  |  Super-gonorrhoea is here – that means the antibiotic crisis is too

    THE GUARDIAN | Highly drug-resistant bugs are no longer a future problem. After decades of complacency, urgency is needed. A commentary by Jeremy Knox

    Full Story

  • 03.29.2018  |  Bug Money

    BIOCENTURY | Despite tremendous public health need, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known classes of small moledcule antibiotics. But some initiatives including CARB-X are backing new mechanisms and preclinical assets that could address resistance for longer.

    Full Story

  • 03.15.2018  |  New thinking is required to create desperately needed new antibiotics. We must act now.

    THE TELEGRAPH | A commentary by Dr. Tim Jinks, Wellcome Trust

    Full Story

  • 03.02.2018  |  Countdown to the last antibiotic. Where is the next generation of antibiotics going to come from?

    CHEMISTRY WORLD | The need for new antibiotics is urgent. Organizations like CARB-X are delivering solutions to the innovation challenge.

    Full Story

  • 02.28.2018  |  Les antibiotiques, oubliés par l’industrie pharmaceutique (Antibiotics, forgotten by the pharmaceutical industry)

    RADIO CANADA | In recent years, major pharmaceutical companies have significantly reduced investments in antibiotic research. The result is an innovation gap and with the steadfast rise in drug resistance, an urgent global need for new antibiotics and other products to fight against drug-resistant bacterial infections. Organizations like CARB-X have stepped in to support innovative research into antibiotics and other products and are making progress.

    Full Story

  • 02.25.2018  |  A new superbug requires urgent attention

    WASHINGTON POST | Typhoid fever is a major public-health menace in low- and middle-income countries it is often transmitted by contaminated water and causes an estimated 200,000 deaths a year

    Full Story

  • 02.16.2018  |  Lung Probe Speeds Detection of Infections

    TECHNOLOGY NETWORKS | Early tests indicate the bedside technology developed by Proteus with help from CARB-X may be able to detect harmful bacteria in patients' lungs in less than 60 seconds.

    Full Story

  • 02.15.2018  |  CARB-X Announces First Award Of 2018; Seeks Partners For Antibacterial Research

    IP WATCH | CARB-X, the private-public partnership for research on antimicrobial resistance, today announced its first award of 2018, nearly $2 million for the development of a new class of antibiotics. Meanwhile, the group has announced it is seeking to partner with accelerator organisations to build its pipeline of early development research projects. It also announced a study that called for a new global approach and greater financial incentives for antibiotic research.

    Full Story

  • 02.15.2018  |  Probe provides rapid lung investigation

    BBC | Proteus technology opens new doors for diagnosing serious drug resistant infections in the lungs.

    Full Story

  • 02.14.2018  |  Antimicrobial Resistance: Forging A New Strategy Against an Old Threat

    CONTAGION LIVE | CARB-X and other initiatives seek to infuse life into the research and development of new drugs.

    Full Story

  • 02.06.2018  |  FDA cites progress, hurdles in antibiotic development

    CIDRAP | A new report from the US Food and Drug Administration (FDA) lays out the progress that's been made in facilitating the development of new antibacterial drugs, but it says additional efforts are needed.

    Full Story